Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone Methyl in Diabetic Nephropathy
NCT00664027Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2008
- Primary completion
- May 2009
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bardoxolone methyl in diabetic nephropathy (DN) (4 arms), sponsored by Biogen. Primary endpoint: Glomerular Filtration Rate at 56 days. Started Apr 2008; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00664027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664027.